Pathologic response to neoadjuvant therapy of high risk prostate cancer

Pathologic response to neoadjuvant therapy of high risk prostate cancer

Background. The role of pathological response, which develops as a result of systemic therapy for localized and locally advanced high risk prostate cancer, is not still fully understood. There are no clear indications for neoadjuvant therapy and no data on the relationship between neoadjuvant therap...

Full description

Bibliographic Details
Main Authors:	M. V. Berkut, A. S. Artemjeva, S. S. Tolmachev, S. A. Reva, S. V. Petrov, A. K. Nosov
Format:	Article
Language:	Russian
Published:	ABV-press 2020-11-01
Series:	Onkourologiâ
Subjects:	prostate cancer radical prostatectomy neoadjuvant therapy chemotherapy hormone therapy pathologic response tumor response
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/1011

Similar Items

Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer
by: M. V. Berkut, et al.
Published: (2020-04-01)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
by: Naiki Taku, et al.
Published: (2012-12-01)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
by: Takeshi Sasaki, et al.
Published: (2021-04-01)

Results of a unicenter randomized study of the safety and efficiency of docetaxel chemotherapy before radical prostatectomy in patients with intermediate- and high-risk prostate cancer: An 11.4-year follow-up
by: A. K. Nosov, et al.
Published: (2014-12-01)

Results of a unicenter randomized study of the safety and efficiency of docetaxel chemotherapy before radical prostatectomy in patients with intermediate- and high-risk prostate cancer: An 11.4-year follow-up
by: A. K. Nosov, et al.
Published: (2014-12-01)

The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
by: Lijin Zhang, et al.
Published: (2021-02-01)

Early recovery program in the radical surgical treatment of patients with prostate cancer: experience of the specialized hospital
by: A. K. Nosov, et al.
Published: (2016-12-01)

Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis
by: Wen Liu, et al.
Published: (2021-01-01)

Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy
by: Cheol Keun Park, et al.
Published: (2016-05-01)

Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience
by: Feryel Letaief, et al.
Published: (2017-06-01)

Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis
by: Jiaqiang Zhang, et al.
Published: (2020-12-01)

Early removal of urethral catheter after endoscopic extraperitoneal radical prostatectomy
by: A. K. Nosov, et al.
Published: (2019-07-01)

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression
by: Krishan R. Jethwa, et al.
Published: (2016-11-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01)

An Investigation of the Pathology Report of Prostate Cancer Patients with Radical Prostatectomy in Southern Iran: A Cross-sectional Study
by: Ali Ariafar, et al.
Published: (2021-01-01)

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review
by: Alessandro Sciarra, et al.
Published: (2016-11-01)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
by: Sungchan Gwark, et al.
Published: (2021-09-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01)

MRI-PATHOLOGICAL PARALLELS WITH THE COMPLETE TUMOR RESPONSE TO NEOADJUVANT CHEMORADIATION TREATMENT OF RECTAL CANCER
by: T. P. Berezoskaya, et al.
Published: (2019-06-01)

PATHOLOGICAL RESPONSE OF GASTRIC CANCER TO NEOADJUVANT PROLONGED CHEMORADIOTHERAPY FOLLOWED BY D2 GASTRECTOMY
by: Е. F. Lushnikov, et al.
Published: (2016-02-01)

Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital
by: Kamal Basri Siregar, et al.
Published: (2017-08-01)

Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study
by: Crystal Seldon, et al.
Published: (2021-03-01)

The role of radical prostatectomy in high-risk prostate cancer
by: Byung Ha Chung
Published: (2013-09-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Neoadjuvant hormonal therapy is associated with comparable outcomes to neoadjuvant chemotherapy in post-menopausal women with estrogen receptor-positive breast cancer
by: David M. Marcus, et al.
Published: (2013-12-01)

The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis
by: Yaling Wang, et al.
Published: (2020-01-01)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
by: Sungchan Gwark, et al.
Published: (2021-07-01)

Radical Prostatectomy is a Valuable Treatment Alternative in Patients with High-Risk Prostate Cancer
by: Naşide Mangır, et al.
Published: (2015-09-01)

Pathological Complete Response following Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma with Mammary Paget’s Disease: A Case Report
by: Wataru Goto, et al.
Published: (2021-08-01)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
by: Phung HT, et al.
Published: (2020-10-01)

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
by: Misun Choi, et al.
Published: (2017-01-01)

The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
by: G A Frank, et al.
Published: (2015-06-01)

RADICAL PROSTATECTOMY WITH EXTENDED PELVIC LYMPHADENECTOMY AND ADJUVANT HORMONAL THERAPY IN PATIENTS WITH LYMPHOGENIC DISSEMINATED PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-08-01)

RADICAL PROSTATECTOMY WITH EXTENDED PELVIC LYMPHADENECTOMY AND ADJUVANT HORMONAL THERAPY IN PATIENTS WITH LYMPHOGENIC DISSEMINATED PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-08-01)

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml
by: Umezawa Rei, et al.
Published: (2011-11-01)

Is Pathologic Complete Response the Surrogate in Primary Gastric Angiosarcoma Undergoing Doxorubicin-Based Neoadjuvant Chemotherapy? A Case Report
by: Zheng CH, et al.
Published: (2020-12-01)

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
by: Sarah L. Savaridas, et al.
Published: (2019-10-01)

Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis
by: Jonathan Klein, et al.
Published: (2019-04-01)

CLINICAL MORPHOLOGICAL CHARACTERISTICS OF THE RESULTS OF NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER
by: Khorov A. O., et al.
Published: (2019-05-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
by: In Hee Lee, et al.
Published: (2020-11-01)